Homology Medicines, Inc. stock is down -43.96% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 5 December’s closed higher than November.
Homology Medicines, Inc. focuses on transforming the lives of patients suffering from rare genetic diseases. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues.